作者
Armeen Mahvash, Ravi Murthy, Bruno C Odisio, Kanwal Pratap Raghav, Lauren Girard, Sheree Cheung, Van Nguyen, Joe Ensor, Sameer Gadani, Khaled M Elsayes, Reham Abdel-Wahab, Manal Hassan, Ahmed S Shalaby, James C Yao, Michael J Wallace, Ahmed O Kaseb
发表日期
2016/2/5
期刊
Journal of hepatocellular carcinoma
页码范围
1-7
出版商
Taylor & Francis
简介
Purpose
The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination therapy in patients with advanced HCC at our institution and analyzed the treatment and survival outcomes.
Materials and methods
We reviewed the records of 19 patients with Barcelona Clinic Liver Cancer class B or C HCC who underwent treatment with Y90 RMS (for 21 sessions) while receiving full or reduced doses of sorafenib between January 2008 and May 2010. Therapy response was evaluated using Response Evaluation Criteria in Solid Tumors. We evaluated median overall survival (OS) and progression-free survival (PFS) as well as hepatic and extrahepatic disease PFS and incidence of adverse events.
Results
The median patient age was 67 years …
学术搜索中的文章
A Mahvash, R Murthy, BC Odisio, KP Raghav, L Girard… - Journal of hepatocellular carcinoma, 2016